Clinical Trials Logo

Triple Negative Breast Neoplasms clinical trials

View clinical trials related to Triple Negative Breast Neoplasms.

Filter by:

NCT ID: NCT04494958 Completed - Clinical trials for Triple Negative Breast Cancer

Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer

PALBOBIN
Start date: November 18, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study is an interventional, prospective, multicentric, single-arm, open label, phase Ib clinical trial. This study will be carried out in patients diagnosed of metastatic or locally advanced unresectable triple negative breast cancer with activation of ERK and/or CDK4/6 in which the following will be assesed: the overall response rate, the aggregation of antitumor effect depending on the different kinome profiles and the safety profile to the combination of palbociclib and binimetinib.

NCT ID: NCT04489940 Terminated - Clinical trials for Triple Negative Breast Neoplasms

Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer

Start date: October 12, 2020
Phase: Phase 2
Study type: Interventional

The main purpose of this study was to evaluate bintrafusp alfa monotherapy in participants with triple negative breast cancer (TNBC) who express high levels of HMGA2 as determined by a centralized reverse transcriptase-polymerase chain reaction (RT-PCR) test.

NCT ID: NCT04481763 Recruiting - Clinical trials for Triple-Negative Breast Cancer

A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast

Start date: July 14, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a open-labeled, single-arm, Investigator-initiated clinical trial of camrelizumab (an anti-PD-1 antibody) in combination with radiotherapy in patients with early triple-negative breast cancer. We will enroll 60 subjects. This study aims to evaluate the efficacy and safety of camrelizumab combined with radiotherapy in the treatment of early TNBC。

NCT ID: NCT04468061 Recruiting - Breast Cancer Clinical Trials

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Start date: July 20, 2020
Phase: Phase 2
Study type: Interventional

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: - Sacituzumab govitecan (Trodelvy™;IMMU-132) - Pembrolizumab (Keytruda®; MK-3475)

NCT ID: NCT04464967 Withdrawn - Colorectal Cancer Clinical Trials

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Start date: March 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the Phase 1/2a study is to evaluate the safety and tolerability of SNK01 in combination with trastuzumab or cetuximab in order to determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), and the preliminary efficacy for each combination regimen.

NCT ID: NCT04464174 Completed - Clinical trials for Triple Negative Breast Cancer

Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer

PATHFINDER
Start date: October 8, 2020
Phase: Phase 2
Study type: Interventional

This is a multicenter, open-label, non-comparative, three-arm, phase IIa trial of Ipatasertib (GDC-0068) in combination with non-taxane chemotherapy agents for taxane-pretreated unresectable locally advanced or metastatic triple-negative breast cancer patients

NCT ID: NCT04461600 Terminated - Clinical trials for Triple Negative Breast Cancer

A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer

TENACITY
Start date: August 14, 2020
Phase: Phase 2
Study type: Interventional

The current study is designed to evaluate the efficacy and safety of AL101 monotherapy in subjects with Notch-activated recurrent or metastatic TNBC; Notch activation will be determined by a Next Generation Sequencing (NGS) test.

NCT ID: NCT04457700 Recruiting - Clinical trials for HER2-positive Breast Cancer

CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC

Start date: November 1, 2020
Phase:
Study type: Observational

This is a prospective, single-center, non-randomized, non-controlled observational study.

NCT ID: NCT04454437 Active, not recruiting - Clinical trials for Metastatic Triple-negative Breast Cancer

Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

Start date: October 23, 2020
Phase: Phase 2
Study type: Interventional

The goal of this study is to learn more about the effectiveness of the study drug, sacituzumab govitecan-hziy, in Chinese participants with metastatic triple-negative breast cancer (mTNBC) who received at least 2 systemic chemotherapy regimens.

NCT ID: NCT04452370 Recruiting - Clinical trials for Triple Negative Breast Cancer

Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer

Start date: September 23, 2020
Phase: Phase 2
Study type: Interventional

The hypothesis of this study is to discover if the oral Etoposide plus Anlotinib can shrink or slow the growth of pretreated advanced TNBC. It is a single-arm, multicenter phase II clinical study of oral etoposide combined with antinib in the treatment of recurrent or metastatic triple-negative breast cancer